Biogen (BIIB) Payables (2009 - 2026)

Biogen's Payables history runs 18 years deep, the most recent figure standing at $358.5 million for Q1 2026.

• In Q1 2026, Payables fell 83.25% year-over-year to $358.5 million; the TTM figure through Mar 2026 stood at $358.5 million (down 83.25% YoY), while the FY2025 annual figure was $432.0 million, down 80.12% from the prior year.
• Payables was $358.5 million for Q1 2026 at Biogen, down from $432.0 million in the prior quarter.
• In the past five years, Payables ranged from a high of $7.7 billion in Q2 2022 to a low of $358.5 million in Q1 2026.
• Historically, Payables has averaged $3.1 billion across 5 years, with a median of $2.1 billion in 2025.
• Biggest YoY gain for Payables was 1954.89% in 2022; the steepest drop was 95.02% in 2022.
• A 5-year view of Payables shows it stood at $6.8 billion in 2022, then rose by 8.4% to $7.3 billion in 2023, then sank by 70.4% to $2.2 billion in 2024, then slumped by 80.12% to $432.0 million in 2025, then retreated by 17.01% to $358.5 million in 2026.
• The last three Payables figures came in at $358.5 million (Q1 2026), $432.0 million (Q4 2025), and $6.7 billion (Q3 2025), per Business Quant data.